Please ensure Javascript is enabled for purposes of website accessibility

Pacira Pharmaceuticals Inc.'s Double-Digit Drop Explained

By Sean Williams - May 2, 2016 at 4:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One figure in Pacira's first-quarter earnings report is worrying Wall Street.

Image source: NIH Image Gallery via Flickr.

What: Shares of Pacira Pharmaceuticals (PCRX -0.76%), a specialty pharmaceutical company primarily focused on the development of medicines to help in the acute hospital care setting, dipped by as much as 10% during Monday's trading session after reporting mixed first-quarter earnings results.

So what: For the quarter, total revenue grew 12% to $65.5 million from the prior-year quarter, with the vast majority of its revenue (97.4%) derived from the sale of Exparel, an injectable treatment designed to relieve pain after surgery. Expenses, however, jumped 23% year over year to $67.7 million. On an adjusted basis, Pacira reported $5.7 million in net income, which works out to $0.15 per share. This is down from the $9.8 million in net income and $0.27 in adjusted EPS it recorded in the year-ago quarter.

Image source: Flickr user Spirit-Fire.

Comparatively, Wall Street had been looking for Pacira to report a smaller adjusted profit of just $0.09 per share. However, it also anticipated total sales closer to $66.8 million, implying that growth of Exparel disappointed in Q1. For what it's worth, Pacira stood by its expectations for $60 million-$70 million in research and development expenses in 2016, as well as $125 million to $135 million in selling, general, and administrative expenses.

Now what: The big concern Wall Street and investors seem to be having is that Exparel's growth rate is slowing. In 2015, Pacira reported $239.9 million in Exparel sales, representing year-over-year growth of 27%. Based on its Q1 2016 results, we could be looking at Exparel's 2016 growth at just half that rate or even less.

Looking ahead, Pacira hopes to reaccelerate growth by capitalizing on label expansion opportunities in Exparel. Later this year, it expects to launch Exparel for use by oral surgery patients. Peak annual sales vary on Wall Street from the mid-$300 million range to nearly $1 billion annually.

If there is some solace here for Pacira shareholders, it's that it remains profitable and boasts a cash, cash equivalent, and short- and long-term investment pile worth $163.5 million as of the end of Q1. This should provide some downside support following today's earnings-based move.

But being so heavily reliant on one drug is a bit worrying. Even with its reduced forward P/E of 22, I'd caution that a deflation in Pacira's market value could continue until we see a stabilized growth rate for Exparel or a more diversified product portfolio.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pacira BioSciences, Inc. Stock Quote
Pacira BioSciences, Inc.
$63.11 (-0.76%) $0.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.